UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 194,542 Shares of Zoetis Inc. (NYSE:ZTS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 5.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,896,106 shares of the company's stock after acquiring an additional 194,542 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.86% of Zoetis worth $761,221,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of ZTS. Mizuho Securities USA LLC raised its position in Zoetis by 13,726.9% during the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company's stock worth $950,524,000 after acquiring an additional 4,829,815 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Zoetis by 4.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company's stock valued at $812,695,000 after purchasing an additional 178,303 shares during the period. Clearbridge Investments LLC lifted its stake in Zoetis by 5.8% in the 2nd quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company's stock valued at $527,774,000 after purchasing an additional 166,517 shares during the last quarter. Principal Financial Group Inc. grew its holdings in Zoetis by 17.3% during the third quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company's stock worth $464,497,000 after purchasing an additional 351,372 shares during the period. Finally, Sarasin & Partners LLP increased its position in Zoetis by 546.3% during the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company's stock worth $390,682,000 after buying an additional 1,904,899 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Stock Performance

Zoetis stock traded up $1.04 during midday trading on Thursday, hitting $176.74. The company's stock had a trading volume of 2,315,768 shares, compared to its average volume of 2,968,865. The company has a 50-day moving average price of $184.18 and a two-hundred day moving average price of $180.78. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a market cap of $79.74 billion, a price-to-earnings ratio of 33.22, a PEG ratio of 2.70 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts' consensus estimates of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm's quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the business earned $1.36 earnings per share. As a group, sell-side analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis's payout ratio is currently 32.52%.

Analyst Ratings Changes

ZTS has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. raised their price objective on Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a research report on Friday, October 11th. Argus upgraded shares of Zoetis to a "strong-buy" rating in a report on Friday, August 9th. BTIG Research increased their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a "buy" rating in a research report on Monday, August 12th. Piper Sandler lifted their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an "overweight" rating in a report on Wednesday, August 14th. Finally, Stifel Nicolaus increased their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a "buy" rating in a report on Wednesday, September 18th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.